- JP-listed companies
- Kubota Pharmaceutical Holdings Co., Ltd.
- Income statement
Kubota Pharmaceutical Holdings Co., Ltd. (4596) Income statement
Market cap
¥11.2B
P/E ratio
Kubota Pharmaceutical develops innovative eye disease treatments including wearable myopia devices and pharmaceuticals for conditions like diabetic retinopathy.
| 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Revenue | 870 | 422 | 260 | 254 | 38 | 173 | 8 | 40 | 27 | 21 |
| Revenue growth (%) | - | |||||||||
| Cost of revenue | - | - | - | - | - | - | 6 | 12 | 5 | 26 |
| Operating margin (%) | ||||||||||
| Operating expenses | - | - | - | - | - | 604 | 601 | 633 | 711 | 543 |
| Operating income | -483 | -436 | -410 | -3,288 | -2,484 | -2,585 | -2,038 | -1,504 | -1,345 | -895 |
| Income before tax | -3,953 | -3,445 | -3,046 | -3,105 | -2,437 | -2,616 | -2,016 | -1,490 | -1,333 | -676 |
| Pretax margin (%) | -454.2 | -815.5 | -1,171.8 | -1,222.6 | -6,450.6 | -1,508.8 | -24,423.4 | -3,734.6 | -4,902.2 | -3,169.7 |
| Provision for income taxes | - | - | - | -40 | - | - | - | - | - | - |
| Effective tax rate (%) | - | - | - | - | - | - | - | - | - | |
| Net income | -3,953 | -3,445 | -3,046 | -3,066 | -2,437 | -2,616 | -2,016 | -1,490 | -1,333 | -676 |
| Earnings per share | -105.64 | -90.85 | -78.42 | -73.06 | -56.9 | -57.46 | -40.92 | -26.79 | -23.65 | -10.59 |
| Diluted EPS | -105.64 | - | -78.42 | -73.06 | -56.9 | -57.46 | -40.92 | -26.79 | -23.65 | -10.59 |
| Dividend payout ratio (%) | - | - | - | - | - | - | - | - | - | - |
| Dividend per share | - | - | - | - | - | - | - | - | - | - |